Sanders Morris Harris LLC Buys 4,000 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Sanders Morris Harris LLC boosted its position in Bausch Health Companies Inc. (NYSE:BHC) by 16.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,975 shares of the company’s stock after acquiring an additional 4,000 shares during the quarter. Sanders Morris Harris LLC’s holdings in Bausch Health Companies were worth $234,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in BHC. Headlands Technologies LLC bought a new position in shares of Bausch Health Companies during the 2nd quarter valued at about $35,000. MQS Management LLC bought a new position in Bausch Health Companies during the second quarter valued at approximately $71,000. Kendall Capital Management bought a new position in Bausch Health Companies during the second quarter valued at approximately $87,000. Brown Brothers Harriman & Co. bought a new stake in shares of Bausch Health Companies in the 2nd quarter worth approximately $109,000. Finally, Seven Eight Capital LP purchased a new stake in shares of Bausch Health Companies in the 2nd quarter valued at $173,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Price Performance

Shares of NYSE:BHC opened at $7.63 on Thursday. The stock’s 50-day moving average is $8.03 and its 200 day moving average is $7.44. The company has a market cap of $2.76 billion, a PE ratio of -15.90 and a beta of 0.69. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $11.46.

Bausch Health Companies (NYSE:BHC) last posted its earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The firm had revenue of $2.51 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the previous year, the firm earned $1.03 earnings per share. The business’s revenue was up 12.2% compared to the same quarter last year. Analysts expect that Bausch Health Companies Inc. will post 3.73 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on BHC shares. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Finally, Royal Bank of Canada raised their price target on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $7.75.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.